培美曲塞联合恩度一线治疗老年晚期肺腺癌的疗效研究

Study on effects of first-line applied pemetrexed with endostar on senile patients with advanced-stage lung adenocarcinoma

目的观察培美曲塞联合恩度一线治疗老年晚期肺腺癌的近期疗效及不良反应。方法选择73例老年晚期肺腺癌患者,随机分为两组。对照组在每疗程(21 d)第1 d给予培美曲塞500 mg/m2,观察组在此基础上,于每疗程(21 d)前14 d给予恩度7.5 mg/m2。3 w为1疗程,治疗2个疗程后,评价近期疗效及不良反应。结果观察组总有效率(48.7%)高于对照组(25.0%),差异有统计学意义(P<0.05),且两组在中性粒细胞下降、血红蛋白下降、血小板下降、白细胞下降、心电图改变等不良反应程度上,均无统计学差异(P>0.05)。结论培美曲塞联合恩度可显著提高老年晚期肺腺癌的治疗效果,且安全性良好,值得临床进一步研究。

Objective To observe the recent curative effects and adverse reaction of first-line applied pemetrexed with endostar on senile patients with advanced-stage lung adenocarcinoma.Methods Total 73 senile patients with advanced-stage lung adenocarcinoma were selected and divided randomly into two groups,i.e.,the control group and observation group.A course of treatment was 21 days.For the control group,pemetrexed of 500 mg /m^2 was administered on the 1st day;for the observation group,besides the same dose of pemetrexed administered on the 1st day,endostar of 7.5 mg /m^2 was administered in the first 14 days.After two course of treatment,the curative effects and adverse reaction were evaluated.Results The total effect of the observation group（48.7%）was better than that of the control group（25.0%）;the difference was statistically significant（P〈0.05）.For adverse reaction,such as neutropenia,decrease of hemoglobin and platelet as well as white blood cells,and ECG changes,there were no statistical differences（P〉0.05）between two groups.Conclusion Application of pemetrexed with endostar can significantly improve the curative effects for senile patients with advanced-stage lung adenocarcinoma;it is safe and is worthy of further clinical study.